Postresection surveillance for pancreatic cancer performance status, imaging, and serum markers

Cancer Journal (United States)

Volumn 18, Issue 6, 2012, Pages 609-613

  O'Reilly, Eileen M ^a,b   Lowery, Maeve A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

optimal surveillance strategy; Pancreatic cancer

Indexed keywords

CA 19-9 ANTIGEN; ERLOTINIB; FLUOROPYRIMIDINE; FLUOROURACIL; GEMCITABINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; FOLLOW UP; HEALTH CARE COST; HUMAN; PANCREAS ADENOCARCINOMA; PANCREAS SURGERY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TREATMENT OUTCOME;

HUMANS; NEOPLASM RECURRENCE, LOCAL; PANCREATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84871229473     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e3182758e27     Document Type: Review

References (56)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
2. Ghaneh P, Costello E, Neoptolemos JP. Biology and management of pancreatic cancer. Gut. 2007;56:1134-1152.
3. Vincent A, Herman J, Schulick R, et al. Pancreatic cancer. Lancet 2011;378:607-620.
4. Van den Broeck A, Sergeant G, Ectors N, et al. Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma. Eur J Surg Oncol. 2009;35:600-604.
5. Hernandez JM, Morton CA, Al-Saadi S, et al. The natural history of resected pancreatic cancer without adjuvant chemotherapy. Am Surg. 2010;76:480-485.
6. Garcea G, Dennison AR, Pattenden CJ, et al. Survival following curative resection for pancreatic ductal adenocarcinoma. A systematic review of the literature. JOP. 2008;9:99-132.
7. Conlon KC, Klimstra DS, Brennan MF. Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg. 1996;223:273-279.
8. Ferrone CR, Brennan MF, Gonen M, et al. Pancreatic adenocarcinoma: the actual 5-year survivors. J Gastrointest Surg. 2008;12:701-706.
9. Adham M, Jaeck D, Le Borgne J, et al. Long-term survival (5-20 years) after pancreatectomy for pancreatic ductal adenocarcinoma: a series of 30 patients collected from 3 institutions. Pancreas. 2008;37:352-357.
10. Ueda M, Endo I, Nakashima M, et al. Prognostic factors after resection of pancreatic cancer. World J Surg. 2009;33:104-110.
11. Birkmeyer JD, Siewers AE, Finlayson EV, et al. Hospital volume and surgical mortality in the United States. N Engl J Med. 2002;346: 1128-1137.
12. McPhee JT, Hill JS, Whalen GF, et al. Perioperative mortality for pan-createctomy: a national perspective. Ann Surg. 2007;246:246-253.
13. Meszoely IM, Lee JS, Ross EA, et al. Patients with resected pancreatic cancer with isolated pulmonary recurrence have improved survival compared to patients with other sites of recurrence. Proc Am Soc Clin Oncol. 2003;22:1488.
14. Sheffield KM, Crowell KT, Lin YL, et al. Surveillance of pancreatic cancer patients after surgical resection. Ann Surg Oncol. 2012;19: 1670-1677.
15. Zhang Y, Frampton AE, Kyriakides C, et al. Loco-recurrence after resection for ductal adenocarcinoma of the pancreas: predictors and implications for adjuvant chemoradiotherapy. J Cancer Res Clin Oncol. 2012;138:1063-1071.
16. Snyder CF, Earle CC, Herbert RJ, et al. Preventive care for colorectal cancer survivors: a 5-year longitudinal study. J Clin Oncol. 2008;26: 1073-1079.
17. Voss SD, Chen L, Constine LS, et al. Surveillance computed tomography imaging and detection of relapse in intermediate-and advanced-stage pediatric hodgkin's lymphoma: a report from the Children's Oncology Group. J Clin Oncol. 2012;30:2635-2640.
18. Renehan AG, Egger M, Saunders MP, et al. Impact on survival of intensive follow-up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ. 2002;324:813.
19. Knopf KB, Warren JL, Feuer EJ, et al. Bowel surveillance patterns after a diagnosis of colorectal cancer in Medicare beneficiaries. Gastrointest Endosc. 2001;54:563-571.
20. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817-1825.
21. Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2011;29:4548-4554.
22. Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24:5313-5327.
23. NCCN clinical practice gudielines in oncology: pancreatic adenocarci-noma. In 2012; Version 2.
24. Tempero MA, Arnoletti JP, Behrman SW, et al. Pancreatic Adenocarci-noma, version 2.2012: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2012;10:703-713.
25. Cascinu S, Falconi M, Valentini V, et al. Pancreatic cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(suppl 5):v55-v58.
26. Yamaguchi K, Tanaka M. EBM-based Clinical Guidelines for Pancreatic Cancer 2009 from the Japan Pancreas Society: a synopsis. Jpn J Clin Oncol. 2011;41:836-840.
27. Kindler HL, Niedzwiecki D, Hollis D, et al. Gemcitabine plus bevacizu-mab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010;28:3617-3622.
28. Chagpar RB, Martin RC, Ahmad SA, et al. Medically managed hyper-cholesterolemia and insulin-dependent diabetes mellitus preoperatively predicts poor survival after surgery for pancreatic cancer. J Gastrointest Surg. 2011;15:551-557.
29. Cannon RM. Multi-institutional analysis of pancreatic adenocarcinoma demonstrating the effect of diabetes status on survival after resection. HPB (Oxford, England). 2012;14:228-235.
30. La Torre M. The Glasgow Prognostic Score as a predictor of survival in patients with potentially resectable pancreatic adenocarcinoma. Ann Surg Oncol. 2012;19:2917-2923.
31. Shabahang M, Marchessault M, Luh J, et al. The effect of close postoperative follow-up on survival outcome of patients with pancreatic cancer. 2010 Gastrointestinal Cancers Symposium. 2010;262.
32. Brenner DJ, Hricak H. Radiation exposure from medical imaging: time to regulate? JAMA. 2010;304:208-209.
33. Brenner DJ, Hall EJ. Computed tomographyVan increasing source of radiation exposure. N Engl J Med. 2007;357:2277-2284.
34. Brenner DJ. Should we be concerned about the rapid increase in CT usage? Rev Environ Health. 2010;25:63-68.
35. Cwik G, Wallner G, Skoczylas T, et al. Cancer antigens 19-9 and 125 in the differential diagnosis of pancreatic mass lesions. Arch Surg. 2006; 141:968-973; discussion 974.
36. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol. 1990;85:350-355.
37. Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adeno-carcinoma: an evidence based appraisal. J Gastrointest Oncol. 2012;3: 105-119.
38. Lamerz R. Role of tumour markers, cytogenetics. Ann Oncol. 1999; 10(suppl 4):145-149.
39. Uchida E, Tempero MA, Burnett DA, et al. Correlative studies on anti-genicity of pancreatic cancer and blood group types. Cancer Detect Prev Suppl. 1987;1:145-148.
40. Tempero MA, Uchida E, Takasaki H, et al. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res. 1987;47:5501-5503.
41. Goggins M. Molecular markers of early pancreatic cancer. J Clin Oncol. 2005;23:4524-4531.
42. Vestergaard EM, Hein HO, Meyer H, et al. Reference values and biological variation for tumor marker CA 19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population. Clin Chem. 1999;45:54-61.
43. Berger AC, Garcia M Jr, Hoffman JP, et al. Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol. 2008;26:5918-5922.
44. Kang CM, Kim JY, Choi GH, et al. The use of adjusted preopera-tive CA 19-9 to predict the recurrence of resectable pancreatic cancer. J Surg Res. 2007;140:31-35.
45. Berger AC, Meszoely IM, Ross EA, et al. Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma. Ann Surg Oncol. 2004;11: 644-649.
46. Sugiura T. Serum CA19-9 is a significant predictor among preoperative parameters for early recurrence after resection of pancreatic adenocarci-noma. J Gastrointest Surg. 2012;16:977-985.
47. Bloomston M, Bekaii-Saab TS, Kosuri K, et al. Preoperative carbohydrate antigen 19-9 is most predictive of malignancy in older jaundiced patients undergoing pancreatic resection. Pancreas. 2006;33:246-249.
48. Humphris JL, Chang DK, Johns AL, et al. The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann Oncol. 2012;23: 1713-1722.
49. Kinsella TJ. The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer. Am J Clin Oncol. 2008;31:446-453.
50. Abdel-Misih SRZ. Failure of normalization of CA19-9 following resection for pancreatic cancer is tantamount to metastatic disease. Ann Surg Oncol. 2011;18:1116-1121.
51. Ferrone CR. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol. 2006;24:2897-2902.
52. Hess V, Glimelius B, Grawe P, et al. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol. 2008;9:132-138.
53. Stemmler J, Stieber P, Szymala AM, et al. Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin? Onkologie. 2003;26:462-467.
54. Ong SL, Sachdeva A, Garcea G, et al. Elevation of carbohydrate antigen 19.9 in benign hepatobiliary conditions and its correlation with serum bilirubin concentration. Dig Dis Sci. 2008;53:3213-3217.
55. O'Neill CB, Atoria CL, O'Reilly EM, et al. Costs and trends in pancreatic cancer treatment. Cancer. 2012;118:5132-5139.
56. Boyd CA, Branch DW, Sheffield KM, et al. Hospital and medical care days in pancreatic cancer. Ann Surg Oncol. 2012;19:2435-2442.